Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Albumin gene (ALB) locus, located on chromosome 4q13.3, encodes serum albumin, the most abundant protein in human plasma. In the field of genetic medicine, this locus is highly valued as a 'genomic safe harbor' for in vivo gene editing due to its exceptionally high transcriptional activity in hepatocytes. By inserting a promoterless therapeutic transgene (such as those encoding clotting factors, lysosomal enzymes, or metabolic enzymes) into the albumin locus using genome-editing tools like Zinc Finger Nucleases (ZFNs), CRISPR/Cas9, or nuclease-free homologous recombination (e.g., GeneRide), researchers can leverage the powerful endogenous albumin promoter to drive the high-level secretion of therapeutic proteins into the bloodstream.
This 'bio-factory' approach is being investigated for the treatment of various monogenic disorders, including Hemophilia B, Lysosomal Storage Diseases (such as Mucopolysaccharidosis types I and II), and Methylmalonic Acidemia (MMA). While the primary physiological role of the albumin gene is to maintain systemic osmotic pressure and transport hormones, fatty acids, and drugs, its therapeutic utility lies in providing a stable, high-output platform for protein replacement therapy. However, therapeutic challenges include potential off-target genomic cleavage, insertional mutagenesis, immune responses to the viral vectors used for delivery, and serious adverse events such as thrombotic microangiopathy (TMA).
Targeted integration of a therapeutic transgene into the endogenous albumin locus via genome editing (e.g., using Zinc Finger Nucleases, CRISPR/Cas9, or nuclease-free homologous recombination) to leverage the high transcriptional activity of the endogenous albumin promoter for systemic protein production.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Albumin gene (ALB).